We hypothesize that taccalonolide AF is less susceptible to Pgp-mediated drug resistance than other microtubule targeting agents due to its irreversible target engagement and that this may provide a unique potential in the treatment of MDR1-expressing, taxane-resistant ovarian cancers. This evidence concerns the gene PGP and ovarian carcinoma.